A Spanish KOL discusses the current CML treatment landscape, including diagnosis and risk stratification. This interview also includes national reimbursements for available therapies and pipeline therapies under consideration to address unmet needs in the indication.

This interview was conducted on January 28, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.